Welcome to the Hope Bio Blog

By Jan Shultis During the last few weeks of 2025, Houston-area clinical research organization Hope Biosciences Research Foundation (HBRF)  received Food and Drug Administration (FDA) authorization to administer Hope Biosciences’ allogeneic (donor) adipose-derived mesenchymal (adult) stem cells (HB-adMSCs) to seven men and women living with Multiple System Atrophy (MSA). As HBRF shared in their announcement , the occasion is noteworthy both for authorization of research in a r

FOR IMMEDIATE RELEASE By Jan Shultis Sugar Land, Texas, 3 February 2026 - A multicenter trial stretching across the southwestern United States is now recruiting patients to investigate whether allogeneic (donor-derived) Hope Biosciences Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) can prevent progression of trauma-induced Acute Kidney Injury (AKI), an abrupt decline in renal function that occurs over hours to days in up to 50% of trauma and burn patients and has few eff

Stem cells manufactured by Hope Biosciences gain FDA authorization for a clinical trial in Crohn's Disease, an incurable autoimmune condition. Learn how and why this trial matters to real people, with real needs.